Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Lori

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Viruses|July 29, 2023
SARS-CoV-2 Inactivation in Aerosol by Means of Radiated MicrowavesAntonio Manna, Davide De Forni, Marco Bartocci, et al.
The Journal of Investigative Dermatology|January 19, 2005
DermaVir: a novel topical vaccine for HIV/AIDSJulianna Lisziewicz, Jeffrey Trocio, Lucia Whitman, et al.
Plos One|September 5, 2008
Beneficial effect of TRAIL on HIV burden, without detectable immune consequencesBrett D Shepard, Davide De Forni, David R McNamara, et al.
Antiviral Therapy|March 26, 2004
Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptionsAndrea Foli, Renato Maserati, Gabriele Barasolo, et al.
Nanomaterials (Basel, Switzerland)|December 22, 2023
In Vitro Antiviral Activity of Hyperbranched Poly-L-Lysine Modified by L-Arginine against Different SARS-CoV-2 VariantsFederico Fiori, Franca Lucia Cossu, Federica Salis, et al.
Current Issues in Molecular Biology|May 27, 2026
Exploring Hydroxytyrosol as a Promising Virucidal Agent: In Silico and In Vitro Insights into Enveloped VirusesHanan El Ouadi, Zineb Rhazzar, Barbara Poddesu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 31, 2013
Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trialBenigno Rodriguez, David M Asmuth, Roy M Matining, et al.
Virology|May 15, 2007
HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3Anthony D Cristillo, Julianna Lisziewicz, Leilei He, et al.
AIDS Research and Human Retroviruses|June 10, 2005
Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potencyFranco Lori, R B Pollard, L Whitman, et al.
ACS Chemical Biology|December 14, 2017
Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 StrainsMattia Mori, Lesia Kovalenko, Savina Malancona, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Viruses|July 29, 2023
SARS-CoV-2 Inactivation in Aerosol by Means of Radiated MicrowavesAntonio Manna, Davide De Forni, Marco Bartocci, et al.
The Journal of Investigative Dermatology|January 19, 2005
DermaVir: a novel topical vaccine for HIV/AIDSJulianna Lisziewicz, Jeffrey Trocio, Lucia Whitman, et al.
Plos One|September 5, 2008
Beneficial effect of TRAIL on HIV burden, without detectable immune consequencesBrett D Shepard, Davide De Forni, David R McNamara, et al.
Antiviral Therapy|March 26, 2004
Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptionsAndrea Foli, Renato Maserati, Gabriele Barasolo, et al.
Nanomaterials (Basel, Switzerland)|December 22, 2023
In Vitro Antiviral Activity of Hyperbranched Poly-L-Lysine Modified by L-Arginine against Different SARS-CoV-2 VariantsFederico Fiori, Franca Lucia Cossu, Federica Salis, et al.
Current Issues in Molecular Biology|May 27, 2026
Exploring Hydroxytyrosol as a Promising Virucidal Agent: In Silico and In Vitro Insights into Enveloped VirusesHanan El Ouadi, Zineb Rhazzar, Barbara Poddesu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 31, 2013
Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trialBenigno Rodriguez, David M Asmuth, Roy M Matining, et al.
Virology|May 15, 2007
HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3Anthony D Cristillo, Julianna Lisziewicz, Leilei He, et al.
AIDS Research and Human Retroviruses|June 10, 2005
Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potencyFranco Lori, R B Pollard, L Whitman, et al.
ACS Chemical Biology|December 14, 2017
Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 StrainsMattia Mori, Lesia Kovalenko, Savina Malancona, et al.
Pageof 5